Venetoclax Plus Inotuzumab for B-ALL
Venetoclax Plus Inotuzumab for B-ALL
Active, not recruiting · NCT05016947 · Registry updated 2026-01-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Venetoclax Plus Inotuzumab for B-ALL | B-cell acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, acute lymphoblastic leukemia, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 1 | 2026-01-29 | NCT05016947 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Dana-Farber Cancer Institute | 324 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institute | Boston | United States | 133 |